Analyst Downgrade Weighs on Intellia Therapeutics Shares

Intellia Therapeutics’ stock is facing renewed pressure following a brief technical rally. While shares closed the previous week with a gain exceeding 5%, the new trading week began with a prominent analyst downgrade to a “Sell” rating. This creates a direct clash between encouraging technical signals and a newly skeptical view of the company’s fundamental outlook.

Amidst the negative analyst sentiment, notable institutional activity has provided some counterbalance. Cathie Wood’s ARK Invest was a significant buyer last week, adding over 216,000 Intellia shares to its ARKK and ARKG funds. This buying interest contributed to a notable recovery: the stock recently touched a weekly high of $12.75, rebounding from a 52-week low Read more...